305 related articles for article (PubMed ID: 28373258)
1. EUropean prospective cohort study on
Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
[TBL] [Abstract][Full Text] [Related]
3. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
[TBL] [Abstract][Full Text] [Related]
4. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
Pang F; Jia XQ; Zhao QG; Zhang Y
Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
[TBL] [Abstract][Full Text] [Related]
5. Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.
Garnier M; Gallah S; Vimont S; Benzerara Y; Labbe V; Constant AL; Siami S; Guerot E; Compain F; Mainardi JL; Montil M; Quesnel C;
BMJ Open; 2019 Feb; 9(2):e024561. PubMed ID: 30782909
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome.
de Maio Carrilho CM; de Oliveira LM; Gaudereto J; Perozin JS; Urbano MR; Camargo CH; Grion CM; Levin AS; Costa SF
BMC Infect Dis; 2016 Nov; 16(1):629. PubMed ID: 27809803
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).
Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J;
BMJ Open; 2017 Jan; 7(1):e013268. PubMed ID: 28115333
[TBL] [Abstract][Full Text] [Related]
9. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Cprek JB; Gallagher JC
Antimicrob Agents Chemother; 2016 Jan; 60(1):669-73. PubMed ID: 26552970
[TBL] [Abstract][Full Text] [Related]
10. Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
Ho CM; Ho MW; Liu YC; Toh HS; Lee YL; Liu YM; Huang CC; Lu PL; Liu CE; Chen YH; Ko WC; Tang HJ; Yu KW; Chen YS; Chuang YC; Wang JH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S24-8. PubMed ID: 22749055
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital.
Igbinosa O; Dogho P; Osadiaye N
Am J Infect Control; 2020 Jan; 48(1):7-12. PubMed ID: 31431290
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by
Guimarães T; Nouér SA; Martins RCR; Perdigão Neto LV; Martins WMBS; Narciso Barbosa AC; Ferreira ALP; Costa SF; Gales AC
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358592
[TBL] [Abstract][Full Text] [Related]
13. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
[TBL] [Abstract][Full Text] [Related]
14. High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region.
Vargas-Alzate CA; Higuita-Gutiérrez LF; López-López L; Cienfuegos-Gallet AV; Jiménez Quiceno JN
Int J Antimicrob Agents; 2018 Apr; 51(4):601-607. PubMed ID: 29277527
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital.
Torres-Gonzalez P; Cervera-Hernandez ME; Niembro-Ortega MD; Leal-Vega F; Cruz-Hervert LP; García-García L; Galindo-Fraga A; Martinez-Gamboa A; Bobadilla-Del Valle M; Sifuentes-Osornio J; Ponce-de-Leon A
PLoS One; 2015; 10(10):e0139883. PubMed ID: 26431402
[TBL] [Abstract][Full Text] [Related]
16. Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to
López-Cortés LE; Rosso-Fernández C; Núñez-Núñez M; Lavín-Alconero L; Bravo-Ferrer J; Barriga Á; Delgado M; Lupión C; Retamar P; Rodríguez-Baño J;
BMJ Open; 2017 Jun; 7(6):e015439. PubMed ID: 28601833
[TBL] [Abstract][Full Text] [Related]
17. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA).
Paniagua-García M; Bravo-Ferrer JM; Pérez-Galera S; Kostyanev T; de Kraker MEA; Feifel J; Palacios-Baena ZR; Schotsman J; Cantón R; Daikos GL; Carevic B; Dragovac G; Tan LK; Raka L; Hristea A; Viale P; Akova M; Cano Á; Reguera JM; Bartoloni A; Florescu SA; Benea S; Bukarica L; Asensio Á; Korten V; Grundmann H; Goossens H; Bonten MJ; Gutiérrez-Gutiérrez B; Rodríguez-Baño J;
Clin Microbiol Infect; 2024 Feb; 30(2):223-230. PubMed ID: 38267096
[TBL] [Abstract][Full Text] [Related]
18. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Asakura T; Ikeda M; Nakamura A; Kodera S
Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
